Immuno-Oncology | Specialty

Dr. Brody on the Role of Immunotherapy in Hodgkin Lymphoma

December 14th 2020

Joshua Brody, MD, discusses the role of immunotherapy in Hodgkin lymphoma.

Dr. Weber on the Toxicities Associated With Immunotherapy in Lung Cancer

December 14th 2020

Jeffrey S. Weber, MD, PhD, discusses the toxicities associated with immunotherapy in lung cancer.

Immunotherapy Finds a Role in Frontline Small Cell Lung Cancer and Mesothelioma

December 14th 2020

Checkpoint inhibitors have failed to improve progression-free survival and overall survival as second-line therapy and maintenance therapy in small cell lung cancer, but this class of agents continue to show encouraging activity worthy of a paradigm shift up front.

Sznol Advocates for More Awareness of Immune-Related Toxicities

December 14th 2020

Mario Sznol, MD, discusses the critical importance of being aware of the immune-related toxicities that could arise when treating patients with cancer, along with the best ways to manage them.

Frontline Pembrolizumab Granted Positive EU Opinion in Metastatic MSI-H, dMMR CRC

December 11th 2020

December 11, 2020 - The European Medicine Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for pembrolizumab monotherapy for the frontline treatment of adult patients with metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer.

MCL Treatment Shifts Away from Chemoimmunotherapy, Enters New Era of Novel Agents and Cellular Therapies

December 4th 2020

With the shift away from chemoimmunotherapy, and the adoption of novel combinations, as well as cellular therapy, the MCL treatment landscape has entered a new era. Looking forward, minimal residual disease is bound to play a critical role in terms of guiding treatment selection.

Adjuvant Nivolumab Displays Survival Benefits in High-Risk Resected Melanoma

December 4th 2020

December 4, 2020 — Adjuvant nivolumab demonstrated clinically meaningful improvements in relapse-free survival, overall survival, and distant metastasis-free survival vs placebo in patients with high-risk resected melanoma, even after accounting for disease stage and post-recurrence survival, supporting the use of the anti–PD-1 antibody as a standard adjuvant therapy.

Immunotherapy Leads the Way in Lung Cancer, but Creates Complex Treatment Decisions

November 27th 2020

Joshua Reuss, MD, discusses the lung cancer armamentarium, the role of immunotherapy combinations, and the significance of biomarkers.

PD-L1 Status Stratifies Immunotherapy Treatment in NSCLC

November 25th 2020

Data from completed studies evaluating immunotherapy in lung cancer alone or in combination with chemotherapy show that a breakdown of populations by PD-L1 status and additional considerations such as toxicity profiles should guide treatment decisions.

Cancer Vaccine AV-GBM-1 Improves PFS in Newly Diagnosed Glioblastoma

November 17th 2020

November 17, 2020 - AV-GBM-1, a personalized cancer vaccine, demonstrated an improvement in progression-free survival in patients with newly diagnosed glioblastoma.

Cabozantinib Plus Nivolumab/Ipilimumab Under Exploration in Intermediate-, Poor-Risk RCC

November 14th 2020

November 14, 2020 - A novel combination comprised of the TKI cabozantinib plus the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab is under exploration in treatment-naïve patients with intermediate or poor risk advanced or metastatic renal cell carcinoma in the phase 3 COSMIC-313 trial.

FDA Approves Pembrolizumab/Chemo for Locally Recurrent Unresectable or Metastatic TNBC

November 13th 2020

November 13, 2020 - The FDA has granted an accelerated approval to pembrolizumab for use in combination with chemotherapy in the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 as determined by an FDA-approved test.

Dr. Zhang on the Combination of LAG525 and Spartalizumab in Advanced Malignancies

November 12th 2020

Tian Zhang, MD, discusses the combination of ieramilimab and spartalizumab in advanced malignancies.

Next-Generation Bispecific Antibody Shows Early Clinical Activity in Advanced Solid Tumors

November 12th 2020

November 12, 2020 - The first-in-class, next-generation, DuoBody-PD-L1×4-1BB bispecific antibody GEN1046 demonstrated promising early activity and an acceptable safety profile in in patients with advanced solid tumors.

Cabozantinib/Pembrolizumab Trial Poised to Improve Efficacy, Safety in Advanced Melanoma

November 12th 2020

November 12, 2020 - In an effort to further improve outcomes without sacrificing tolerability, the combination of cabozantinib with pembrolizumab is being evaluated in patients with advanced melanoma in a phase 1b/2 study.

KEYNOTE-598 Trial Examining Pembrolizumab/Ipilimumab in NSCLC Stopped for Futility

November 10th 2020

The phase 3 KEYNOTE-598 trial evaluating the dual immunotherapy combination comprised of pembrolizumab and ipilimumab as frontline treatment in patients with metastatic non–small cell lung cancer who have a PD-L1 tumor proportion score of 50% or greater and do not harbor any EGFR or ALK aberrations has been discontinued.

TMB Shows Potential as Immunotherapy Biomarker in Lung Cancer, But Challenges Remain

November 7th 2020

Tumor mutational burden has been associated with response to immunotherapy in patients with lung cancer, but there have been various criticisms regarding the validity and routine use of this as a biomarker.

Nivolumab/Ipilimumab Plus Chemo Approved in Europe for Frontline Metastatic NSCLC

November 6th 2020

The European Commission has approved the combination of nivolumab plus ipilimumab with 2 cycles of platinum-based chemotherapy for the up-front treatment of adult patients with metastatic non–small cell lung cancer without a sensitizing EGFR mutation or an ALK translocation.

JTCC and Georgetown’s Alliance in Cancer Research Achieves New Level With Immunotherapy Breakthrough

November 4th 2020

It was 5:00 PM on a Monday, and Andrew Pecora, MD, FACP, CPE, was just wrapping up his practice for the day when one of his nurses came to the door, asking if he could see one more patient.

Dr. Patel on the Role of Immunotherapy Combinations in Lung Cancer

November 2nd 2020

Sandip P. Patel, MD, discusses the role of immunotherapy combinations in lung cancer.